Αρχική World News Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain... World News Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active Brain Metastases of Breast Cancer and NSCLC Από Ogkologos - 29 Οκτωβρίου, 2025 433 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the cohorts 1 and 2 of the TUXEDO-3 study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ΚΑΡΚΙΝΟΣ ΘΥΡΕΟΕΙΔΟΥΣ ΑΔΕΝΑ 22 Ιουλίου, 2019 Foodie Fridays: Apple Bok Choy Salad 17 Σεπτεμβρίου, 2021 New on NCI’s Websites for March 2021 25 Μαρτίου, 2021 Low-Dose Adjuvant Aspirin Decreases Incidence of Recurrence Among Patients with Resected... 30 Σεπτεμβρίου, 2025 Φόρτωση περισσοτέρων HOT NEWS FDA Approves Tepotinib for Metastatic Non-Small Cell Lung Cancer What to Know About Treatment Options Before and After Surgery for... Many Older Adults Screened Unnecessarily for Common Cancers EMA Recommends Granting a Conditional Marketing Authorisation for Mosunetuzumab